NovoCure Ltd — Director's Dealing 2022

Jan 12, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2022-01-06

Reporting Person: Cordova Ashley (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-01-06	Ordinary Shares	A	46	$63.818	Acquired	41804	Direct

Footnotes

F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2021 through December 31, 2021. This transaction is also exempt under Rule 16b-3(c).

F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on December 31, 2021.